Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer.
| Image |  |
|---|---|
| Description | scientific article published on 27 February 2018 |
| Author/s |
author: Philippe Giron Carolien Eggermont |
| Publication date | February 27, 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |